BSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,761.00
- Market cap
- ₹4,22,523 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 34.9×Sector 48.7×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Sun Pharmaceutical Industries Business Update
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Sun Pharmaceutical Industries Other Announcement
Sun Pharmaceutical Industries submitted the quarterly confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, as received from their RTA.
Sun Pharmaceutical Industries Credit Rating
Sun Pharma received credit ratings from CRISIL and ICRA for its proposed NCD programme and reaffirmed existing facility ratings.
Sun Pharmaceutical Industries Management Change
Sun Pharmaceutical Industries announced the resignation of Independent Director Gautam Doshi due to personal reasons.
Other business update announcements
All →Wanbury Business Update
Wanbury's Tanuku plant received an Australian TGA GMP certificate covering six APIs. This strengthens the company's global pharmaceutical manufacturing credentials.
eMudhra Business Update
eMudhra appointed KPMG to conduct an independent review of a previously reported incident. This follows the company's October 21 press release commitment to engage an external reviewer.
Escorts Kubota Business Update
Escorts Kubota announced a tractor price increase across Kubota, Farmtrac, and Powertrac brands effective November 2026. The revision addresses sustained input cost pressures from geopolitical and rupee-related headwinds.
Lords Mark Industries Business Update
Lord's Mark showcased defence products from its investee Brahamastra, including BRAK RT and TRC-1. The promotional release discloses no orders, revenue, or quantified investment amount.
Rubicon Research Business Update
Rubicon Research disclosed a USFDA inspection of its Ambernath facility, which issued five procedural Form 483 observations. No monetary penalty or amount is involved.
Studio LSD Business Update
Studio LSD Limited provided a business update for Q2 FY27, highlighting operational milestones in television episode counts, OTT series production, theatrical film releases, and music catalogue licensing.